Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733089 | 0.84 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL3517149 | 0.83 | — | — | |
| SCHEMBL781569 | 0.81 | TRPA1 (0.33) | ALDH1A1 | |
| SCHEMBL4098534 | 0.80 | MGAM (0.41) | — | |
| SCHEMBL1177488 | 0.79 | — | — | |
| SCHEMBL19549311 | 0.79 | TSHR (0.34) | — | |
| SCHEMBL11877737 | 0.76 | — | — | |
| SCHEMBL5785547 | 0.76 | — | — | |
| SCHEMBL15110455 | 0.73 | — | — | |
| SCHEMBL7158008 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335454-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | Hangzhou Grand Biologic Pharmaceutical Inc. (CN) | 2024-03-13 | — | — | EP | claimed |
| US-20230346959-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | HANGZHOU GRAND BIOLOGIC PHARMACEUTICAL INC. (CN) | 2023-11-02 | — | — | US | claimed |
| US-20230346896-A1 | METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE | HANGZHOU GRAND BIOLOGIC PHARMACEUTICAL INC. (CN) | 2023-11-02 | — | — | US | claimed |
| EP-4241841-A1 | METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE | Hangzhou Grand Biologic Pharmaceutical Inc. (CN) | 2023-09-13 | — | — | EP | claimed |
| US-20150224207-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLYMER DERIVATIVES | NEKTAR THERAPEUTICS | 2015-08-13 | — | — | US | claimed |
| US-7910661-B2 | Thiol-selective water-soluble polymer derivatives | NEKTAR THERAPEUTICS (US) | 2011-03-22 | — | — | US | claimed |
| JP-4490413-B2 | — | — | 2010-06-23 | — | — | JP | claimed |
| JP-2006517600-A | — | — | 2006-07-27 | — | — | JP | claimed |
| EP-1581582-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLMER DERIVATIVES | Nektar Therapeutics Al, Corporation (US) | 2005-10-05 | — | — | EP | claimed |
| US-20050014903-A1 | Polymer coupling to thiol group containing compound; activation | NEKTAR THERAPEUTICS | 2005-01-20 | — | — | US | claimed |
| WO-2004063250-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLMER DERIVATIVES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2004-07-29 | — | — | WO | claimed |
| EP-3408400-B1 | ANTIGEN BINDING PROTEINS THAT BIND PD-L1 | YUHAN CORP (KR) | 2024-06-26 | — | — | EP | disclosed |
| US-20240190959-A1 | Antigen Binding Proteins that Bind PD-L1 | YUHAN CORPORATION (KR) | 2024-06-13 | — | — | US | disclosed |
| US-11993630-B2 | Method for purifying PEGylated erythropoietin | Hoffmann-La Roche Inc (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4335454-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | Hangzhou Grand Biologic Pharmaceutical Inc. (CN) | 2024-03-13 | — | — | EP | disclosed |
| US-20040110685-A1 | Scatter factor/hepatocyte growth factor antagonist NK4 for the treatment of glioma | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | US | disclosed |
| WO-2004019991-A2 | SCATTER FACTOR/HEPATOCYTE GROWTH FACTOR ANTAGONIST NK4 FOR THE TREATMENT OF GLIOMA | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| EP-1389132-A2 | PEG-CONJUGATES OF HGT-NK4 | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-18 | — | — | EP | disclosed |
| US-20030012775-A1 | PEG conjugates of NK4 | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002074344-A2 | PEG-CONJUGATES OF HGT-NK4 | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012775-A1 | PEG conjugates of NK4 | IL4, PBK, FUT4 | ALDH1A1 3042/4885CYP1A2 3692/4885HPGD 3166/4885 |
| US-20150224207-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLYMER DERIVATIVES | TST, PWWP2B, PDIA6 | ALDH1A1 2893/4885CYP1A2 4713/4885HPGD 775/4885 |
| US-11993630-B2 | Method for purifying PEGylated erythropoietin | EPOR, PDGFRA, TFRC | ALDH1A1 4372/4885CYP1A2 4835/4885HPGD 1846/4885 |
| US-20040110685-A1 | Scatter factor/hepatocyte growth factor antagonist NK4 for the treatment of glioma | HDGF, HGF, HDGFL3 | ALDH1A1 2277/4885CYP1A2 4829/4885HPGD 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.